These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14512867)

  • 21. Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy.
    Cao F; Donlin MJ; Turner K; Cheng X; Tavis JE
    J Viral Hepat; 2011 May; 18(5):349-57. PubMed ID: 20529202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
    Hofmann WP; Zeuzem S; Sarrazin C
    J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare haplotype load as marker for lethal mutagenesis.
    Gregori J; Soria ME; Gallego I; Guerrero-Murillo M; Esteban JI; Quer J; Perales C; Domingo E
    PLoS One; 2018; 13(10):e0204877. PubMed ID: 30281674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
    Nakamura M; Saito H; Ikeda M; Tada S; Kumagai N; Kato N; Shimotohno K; Hibi T
    J Med Virol; 2008 Apr; 80(4):632-9. PubMed ID: 18297719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
    Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
    Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
    Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.
    Mejer N; Fahnøe U; Galli A; Ramirez S; Benfield T; Bukh J
    J Gen Virol; 2018 Aug; 99(8):1066-1077. PubMed ID: 29927371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.
    Kulkarni AS; Damha MJ; Schinazi RF; Mo H; Doehle B; Sagan SM; Götte M
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2018-27. PubMed ID: 26824949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
    Lutchman G; Danehower S; Song BC; Liang TJ; Hoofnagle JH; Thomson M; Ghany MG
    Gastroenterology; 2007 May; 132(5):1757-66. PubMed ID: 17484873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients.
    Castilho MC; Martins AN; Horbach IS; Perez Rde M; Figueiredo FA; Pinto Pde T; Nabuco LC; Lima DB; Tanuri A; Porto LC; Ferreira Júnior Oda C
    Mem Inst Oswaldo Cruz; 2011 Dec; 106(8):968-75. PubMed ID: 22241118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
    Brochot E; Bodeau S; Duverlie G
    Ther Drug Monit; 2015 Aug; 37(4):550-1. PubMed ID: 25525764
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
    Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
    J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon.
    Saito Y; Escuret V; Durantel D; Zoulim F; Schinazi RF; Agrofoglio LA
    Bioorg Med Chem; 2003 Aug; 11(17):3633-9. PubMed ID: 12901908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
    Okanoue T; Itoh Y; Hashimoto H; Yasui K; Minami M; Takehara T; Tanaka E; Onji M; Toyota J; Chayama K; Yoshioka K; Izumi N; Akuta N; Kumada H
    J Gastroenterol; 2009; 44(9):952-63. PubMed ID: 19517057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance of high fitness hepatitis C virus to lethal mutagenesis.
    Gallego I; Gregori J; Soria ME; García-Crespo C; García-Álvarez M; Gómez-González A; Valiergue R; Gómez J; Esteban JI; Quer J; Domingo E; Perales C
    Virology; 2018 Oct; 523():100-109. PubMed ID: 30107298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.